MedTrace Logo

Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

NCT02918123 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-03-14

No results posted yet for this study

Summary

Phase I clinical trial to evaluate safety of FURESTEM-CD Inj. in patients with moderate to severe in plaque-type psoriasis injection for 4weeks.

Conditions

Interventions

BIOLOGICAL

FURESTEM-CD Inj.

Patients will be treated FURESTEM-CD Inj. Subcutaneous injection

Sponsors & Collaborators

  • Kang Stem Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taeyoon Kim · Seoul St. Mary's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-17
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02918123 on ClinicalTrials.gov